Evidence map›Paper›PMID 29296198›Full record

ArticleOncotarget2017

Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors.

María Laura Gutiérrez, Luis Antonio Corchete, María Eugenia Sarasquete, María Del Mar Abad, Oscar Bengoechea, Encarna Fermiñán, María Fernanda Anduaga, Sofía Del Carmen, Manuel Iglesias, Carmen Esteban and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Increased Expression ofJournal of personalized medicine · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

María Laura GutiérrezCytometry Service-NUCLEUS, Cancer Research Center, IBMCC-CSIC/USAL, Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca, Biomedical Research Networking Centre Consortium-CIBER-CIBERONC, Salamanca, Spain.
Luis Antonio CorcheteCancer Research Center and Service of Hematology, University Hospital of Salamanca, Salamanca, Spain.
María Eugenia SarasqueteCancer Research Center and Service of Hematology, University Hospital of Salamanca, Salamanca, Spain.
María Del Mar AbadDepartment of Pathology, University Hospital of Salamanca, Salamanca, Spain.
Oscar BengoecheaDepartment of Pathology, University Hospital of Salamanca, Salamanca, Spain.
Encarna FermiñánGenomics Unit, Cancer Research Center, IBMCC-CSIC/USAL, Salamanca, Spain.
María Fernanda AnduagaService of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
Sofía Del CarmenDepartment of Pathology, University Hospital of Salamanca, Salamanca, Spain.
Manuel IglesiasService of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
Carmen EstebanService of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
María AngosoService of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
Jose Antonio AlcazarService of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
Jacinto García *Service of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
Alberto Orfao *Cytometry Service-NUCLEUS, Cancer Research Center, IBMCC-CSIC/USAL, Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca, Biomedical Research Networking Centre Consortium-CIBER-CIBERONC, Salamanca, Spain.
Luis Muñoz-Bellvís *Service of General and Gastrointestinal Surgery, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
José María Sayagués *Cytometry Service-NUCLEUS, Cancer Research Center, IBMCC-CSIC/USAL, Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca, Biomedical Research Networking Centre Consortium-CIBER-CIBERONC, Salamanca, Spain.
Centro de Investigación del Cáncer · ESUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant advances have been achieved in the genetic characterization of sporadic colorectal cancer (sCRC), the precise genetic events leading to the development of distant metastasis remain poorly understood. Thus, accurate prediction of metastatic disease in newly-diagnosed sCRC patients remains a challenge. Here, we evaluated the specific genes and molecular pathways associated with the invasive potential of colorectal tumor cells, through the assessment of the gene expression profile (GEP) of coding and non-coding genes in metastatic (MTX) vs. non-metastatic (non-MTX) primary sCRC tumors followed for >5 years. Overall, MTX tumors showed up-regulation of genes associated with tumor progression and metastatic potential while non-MTX cases displayed GEP associated with higher cell proliferation, activation of DNA repair and anti-tumoral immune/inflammatory responses. Based on only 19 genes a specific GEP that classifies sCRC tumors into two MTX-like and non-MTX-like molecular subgroups was defined which shows an independent prognostic impact on patient overall survival, particularly when it is combined with the lymph node status at diagnosis. In summary, we show an association between the global GEP of primary sCRC cells and their metastatic potential and defined a GEP-based classifier that provides the basis for further prognostic stratification of sCRC patients who are at risk of distant metastases.

Indexed as

gene expression profilemetastaticnon-metastaticprimary tumorsporadic colorectal cancer

Identifiers

PMID29296198
PMCPMC5746100
OpenAlexW2768835148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.